Healthcare Industry News: HSMN NewsFeed
News Release - April 15, 2019
Data on Impact of Revised Consensus Recommendations on Time to Treatment and Serum Creatinine (SCr) at Treatment Start for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Presented at the 2019 International Liver Congress(TM) (EASL)Retrospective analysis showed applying latest International Club of Ascites (ICA) diagnostic criteria would be estimated to result in earlier time to treatment at a lower SCr level and potentially improved outcomes
STAINES-UPON-THAMES, United Kingdom, April 15, 2019 -- (Healthcare Sales & Marketing Network) -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, is reporting data from a retrospective analysis of data from the Phase 3 REVERSE trial to estimate the impact of applying the revised International Club of Ascites (ICA) diagnostic criteria for Hepatorenal Syndrome Type 1 (HRS-1) on timing of treatment and serum creatinine (SCr) at treatment start. The data were shared on April 13 at the 2019 International Liver Congress™ of the European Association for the Study of the Liver (EASL) in Vienna, Austria.
HRS-1 is a rare and acute disease characterized by the development of rapid kidney failure in patients with advanced chronic liver disease. Prior to 2015, the traditional definition of HRS-1 was a twofold increase of SCr to a level greater than 2.5 mg/dL during a period of less than two weeks. In 2015, the ICA revised consensus recommendations for the diagnosis of HRS-1 based on a dynamic change in SCr in patients with cirrhosis, in order to support earlier treatment of HRS-1.
"HRS-1 has an extremely poor prognosis if left untreated and patients often do not live beyond a few weeks after diagnosis," said Florence Wong, M.D., Professor, GI Division, Department of Medicine, University of Toronto, Toronto General Hospital. "This analysis is important because serum creatinine level has been shown to be a predictor of HRS reversal and potentially improved outcomes. Therefore, it is imperative that time to treatment be as short as possible after diagnosis before progression of HRS, i.e., a higher pre-treatment serum creatinine level."
The poster, "The Diagnosis of Hepatorenal Syndrome (HRS): How Much Does Use of the 2015 Revised Consensus Recommendations Affect Earlier Treatment and Serum Creatinine (SCr) at Treatment Start?" [Poster #SAT-141] can be accessed here.
The study is a retrospective analysis of pre-enrollment serial SCr data from 141 of the 196 patients enrolled in the REVERSE trial for which data were available for this analysis. Researchers assessed the mean number of days between diagnosing HRS-1 using the revised and the traditional criteria. SCr at diagnosis was compared using the revised and the traditional criteria to estimate the effect of the revised criteria on SCr at the potential start of vasoconstrictor therapy.
- Applying revised ICA Acute Kidney Injury-HRS diagnostic criteria rather than traditional HRS-1 diagnostic criteria would be estimated to result in:
- Earlier treatment by approximately four days
- SCr level at initiation of treatment would be on average approximately 1 mg/dL lower
- Almost half (47 percent) of patients would receive treatment before a further ≥ 1.5-fold increase in SCr
This study is a retrospective analysis of a previously completed clinical trial. Results were based on a statistical model that was not specified or measured in the original clinical trial. Results do not imply cause and effect and may be incomplete.
"HRS-1 is a diagnosis of exclusion; initiating treatment takes time. This analysis underscores the need for urgency in utilizing the newer diagnostic criteria in facilitating earlier treatment for HRS-1 patients in order to facilitate potentially better outcomes for patients," said Tunde Otulana, M.D., Senior Vice President and Chief Medical Officer at Mallinckrodt. "We are committed to supporting best practices for patients with HRS-1, including diagnostic criteria that can potentially improve the treatment paradigm."
About Hepatorenal Syndrome Type 1
Hepatorenal Syndrome Type 1 (HRS-1) is a rare and acute disease characterized by the development of rapid kidney failure in patients with advanced chronic liver disease.1 HRS-1 has a very poor prognosis, with a median survival time of less than two weeks and greater than 80 percent mortality within three months., At present, there are no approved drug therapies for HRS-1 treatment in the U.S. or Canada.
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics. Its Specialty Generics and Amitiza reportable segment includes specialty generic drugs, active pharmaceutical ingredients and AMITIZA® (lubiprostone). To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
CAUTIONARY STATEMENTS RELATED TO FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements with regard to the study described in this release, including the potential impact on patients. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; issues with product quality, manufacturing or supply, or patient safety issues; and other risks identified and described in more detail in the "Risk Factors" section of Mallinckrodt's most recent Annual Report on Form 10-K and other filings with the SEC, all of which are available on its website. The forward-looking statements made herein speak only as of the date hereof and Mallinckrodt does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.
Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.
© 2019 Mallinckrodt
1 National Organization for Rare Disorders. Hepatorenal Syndrome. Available at: https://rarediseases.org/rare-diseases/hepatorenal-syndrome/. Accessed October 29, 2018.
2 Colle I and Laterre PF. Hepatorenal syndrome: the clinical impact of vasoactive therapy, Expert Review of Gastroenterology & Hepatology. (2018) 12:2, 173-188, DOI: 10.1080/17474124.2018.1417034.
3 Gines P, Sola E, Angeli P, et al. Hepatorenal syndrome. Nature Reviews. (2018) 4:23.
4 Boyer TD, Medicis JJ, Pappas SC, et al. A randomized, placebo-controlled, double-blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design. Open Access Journal of Clinical Trials 2012:4. https://www.dovepress.com/a-randomized-placebo-controlled-double-blind-study-to-confirm-the-reve-peer-reviewed-article-OAJCT.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsMallinckrodt To Make An Equity Investment In Silence Therapeutics As Part Of A Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases
Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases
Mallinckrodt Updates Plans for Company Separation and Spin-Off of Specialty Generics Business to Shareholders